Inhibitor development as switching full-lengthrecombinant FVIII to B-domain deleted recombinantFVIII in previously treated patients with hemophilia A:Taiwan’s experience

Chia-Yau Chang; S-H Chen; G-C Yeh; C-H Tsai; J-R Tsai; Y-L Liu

Inhibitor development as switching full-lengthrecombinant FVIII to B-domain deleted recombinantFVIII in previously treated patients with hemophilia A:Taiwan’s experience

Chia-Yau Chang, S-H Chen, G-C Yeh, C-H Tsai , J-R Tsai, Y-L Liu

Research output: Contribution to journal › Special issue › peer-review

Abstract

Background:The previous studies revealed that no increased risk ofinhibitor development was seen in patients with hemophilia (PWH)switching from full-length rFVIII (FL-rFVIII) to B-domain deletedrFVIII. Most of these studies came from West countries, and experi-ence from Asian countries was much less.
Aims:We aim to report our experience of switching to Moroctocogalfa (AF-CC) in previously treated patients (PTPs) with hemophilia Ain Taiwan.Methods:As AF-CC had been used in Taiwan since 2012, PTPs whoexperienced treatment of AF-CC switching from FL-rFVIII in ShuangHo Hospital from 2012 to Dec. 2014 were enrolled. Data of age, sever-ity, and inhibitor status were collected and analyzed.

Original language	English
Article number	PO289-WED
Pages (from-to)	856-857
Number of pages	1
Journal	Journal of Thrombosis and Haemostasis
Volume	13
Issue number	S2
Publication status	Published - Jun 2015

Cite this

Inhibitor development as switching full-lengthrecombinant FVIII to B-domain deleted recombinantFVIII in previously treated patients with hemophilia A:Taiwan’s experience. / Chang, Chia-Yau; Chen, S-H; Yeh, G-C et al.
In: Journal of Thrombosis and Haemostasis, Vol. 13, No. S2, PO289-WED, 06.2015, p. 856-857.

Research output: Contribution to journal › Special issue › peer-review

@article{3106146d4d4c4a2d973504843ffddd0c,

title = "Inhibitor development as switching full-lengthrecombinant FVIII to B-domain deleted recombinantFVIII in previously treated patients with hemophilia A:Taiwan{\textquoteright}s experience",

abstract = "Background:The previous studies revealed that no increased risk ofinhibitor development was seen in patients with hemophilia (PWH)switching from full-length rFVIII (FL-rFVIII) to B-domain deletedrFVIII. Most of these studies came from West countries, and experi-ence from Asian countries was much less.Aims:We aim to report our experience of switching to Moroctocogalfa (AF-CC) in previously treated patients (PTPs) with hemophilia Ain Taiwan.Methods:As AF-CC had been used in Taiwan since 2012, PTPs whoexperienced treatment of AF-CC switching from FL-rFVIII in ShuangHo Hospital from 2012 to Dec. 2014 were enrolled. Data of age, sever-ity, and inhibitor status were collected and analyzed.",

author = "Chia-Yau Chang and S-H Chen and G-C Yeh and C-H Tsai and J-R Tsai and Y-L Liu",

year = "2015",

month = jun,

language = "English",

volume = "13",

pages = "856--857",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Elsevier B.V.",

number = "S2",

}

TY - JOUR

T1 - Inhibitor development as switching full-lengthrecombinant FVIII to B-domain deleted recombinantFVIII in previously treated patients with hemophilia A:Taiwan’s experience

AU - Chang, Chia-Yau

AU - Chen, S-H

AU - Yeh, G-C

AU - Tsai , C-H

AU - Tsai, J-R

AU - Liu, Y-L

PY - 2015/6

Y1 - 2015/6

N2 - Background:The previous studies revealed that no increased risk ofinhibitor development was seen in patients with hemophilia (PWH)switching from full-length rFVIII (FL-rFVIII) to B-domain deletedrFVIII. Most of these studies came from West countries, and experi-ence from Asian countries was much less.Aims:We aim to report our experience of switching to Moroctocogalfa (AF-CC) in previously treated patients (PTPs) with hemophilia Ain Taiwan.Methods:As AF-CC had been used in Taiwan since 2012, PTPs whoexperienced treatment of AF-CC switching from FL-rFVIII in ShuangHo Hospital from 2012 to Dec. 2014 were enrolled. Data of age, sever-ity, and inhibitor status were collected and analyzed.

AB - Background:The previous studies revealed that no increased risk ofinhibitor development was seen in patients with hemophilia (PWH)switching from full-length rFVIII (FL-rFVIII) to B-domain deletedrFVIII. Most of these studies came from West countries, and experi-ence from Asian countries was much less.Aims:We aim to report our experience of switching to Moroctocogalfa (AF-CC) in previously treated patients (PTPs) with hemophilia Ain Taiwan.Methods:As AF-CC had been used in Taiwan since 2012, PTPs whoexperienced treatment of AF-CC switching from FL-rFVIII in ShuangHo Hospital from 2012 to Dec. 2014 were enrolled. Data of age, sever-ity, and inhibitor status were collected and analyzed.

UR - https://doi.org/10.1111/jth.12993

M3 - Special issue

SN - 1538-7933

VL - 13

SP - 856

EP - 857

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - S2

M1 - PO289-WED

ER -

Inhibitor development as switching full-lengthrecombinant FVIII to B-domain deleted recombinantFVIII in previously treated patients with hemophilia A:Taiwan’s experience

Abstract

Other files and links

Fingerprint

Cite this